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Objectives: to compare the amputation rates, quality of life and health care costs in patients receiving duplex ultrasound
scanning against clinical surveillance following femoropopliteal and femorocrural vein bypass.
Design: multi-centre, prospective, randomised controlled trial.
Methods: 1200 patients with a patent vein graft at 30 days postoperatively will be randomised to either clinical or
duplex follow-up. All patients are seen in an out-patient clinic at 6 weeks, then 3, 6, 9, 12 and 18 months postoperatively.
At each appointment patients are examined clinically; palpable pulses in the graft and crural vessels, presenting symptoms
and their ankle–branchial pressure indices (ABPIs) measured. In the duplex group only, the results of the scan are
monitored. The incidence of radiological and/or surgical interventions throughout the follow-up period are also noted.
Quality of life is measured using the SF-36 and EuroQol questionnaires at the 6 and 18 month appointments. Hospital
stays and resource use are documented for health economic analysis.
Results: the primary endpoint of this study is amputation or death from vascular causes; however, graft patency rates
will also be compared between the groups. Quality of life and health economic data will be used to determine if there is
any benefit in either arm in these outcomes between follow-up strategies.
Conclusions: this large, randomised-controlled trial will hopefully provide direct evidence on the benefit of duplex
surveillance for vein grafts in terms of limb salvage, quality of life of the patients and cost-benefit to the purchaser.
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Introduction randomised controlled trials. These studies have
indicated that there may be a benefit in terms of
primary assisted patency, when grafts have beenInfrainguinal vein graft procedures are routinely
followed in a duplex surveillance programme.6performed on patients with lower limb peripheral
However, the results of amputation rates were notarterial disease. Autologous vein is usually the
consistently reported, which is the main clinicallypreferred conduit of choice, although prosthetic
important outcome.materials perform well, especially above the knee.1
Despite a number of publications supporting theVein grafts are still prone to complications, with
use of duplex scanning as a valuable tool in detectingapproximately 30% developing stenoses within the
vein graft stenoses, it is still not universally accepted.first year.2,3 The most common cause of such lesions
A recent survey of 112 vascular consultants in theis focal myointimal hyperplasia within the body
U.K. reported the absence of duplex surveillance inof a graft or at the proximal or distal anastomoses.4
a significant proportion of both teaching hospitalsThe role of duplex ultrasound scanning in the
(22%) and district general hospitals (44%). Thesurveillance of infrainguinal bypasses had been
reasons stated for failure to use duplex were eitherreviewed previously.5 Most studies have been retro-
insufficient resources or a lack of belief in its ef-spective analyses or prospective studies with his-
ficacy.11torical controls,7–10 but there are no large
Duplex ultrasound scanning facilities are ex-
*Please address all correspondence to: P. L. Kirby, Department of pensive to establish and maintain. The initial outlay
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technologist or radiographer and the extra costs of†The holders of the British Heart Foundation grant supporting the
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findings must all be considered. Grigg et al. estimated lowing femorodistal vein bypass in terms of limb
salvage.that, if duplex surveillance of all vein grafts pre-
vented 1–2% of patients from needing an am-
putation, then the saving would be great enough to
Methods: Study Designjustify the expense of establishing a surveillance
programme.12
Patients undergoing vein bypass for critical ischaemia,Duplex may prevent amputation through the de-
claudication or symptomatic popliteal aneurysm maytection of early stenoses, thereby offering a chance
be suitable for entry into the Vein Graft Surveillanceof early surgical correction. However, this may not
Trial. They must satisfy the following criteria: (i)always be advantageous; the techniques used to
patients undergoing either femoropopliteal or femoro-correct failing grafts, such as balloon angioplasty or
crural vein bypass; (ii) vein graft patent at 30 daysintervening surgery, may introduce extra risks to the
after operation; (iii) must be able to give informedpatency of that graft. It has been suggested that
consent; (iv) have no significant co-morbidity thata radiological or surgical intervention procedure,
makes life expectancy less than six months; (v) noperformed to correct a stenosis, might increase the
terminal illness. Synthetic grafts such as poly-chance of a recurrence of the stenosis or development
tetrafluoroethylene (PTFE) are excluded from theof a second lesion.2,3,7
study.In addition, it is not known whether detected
Patients are recruited from participating centres ap-stenoses will necessarily threaten graft patency.13–15
proximately six weeks post-bypass and randomisedA small study suggested that conservative treatment
to either the clinical group (clinical examination withof non-haemodynamically significant stenoses had
ABPI measurements) or duplex group (as clinical plusa 12-month patency rate of only 58%, although the
a routine duplex scan). Patients are required to attendmajority of these patients avoided amputation of
for follow-up appointments at the time of recruitmenttheir limb despite having occluded grafts.14 Indeed,
(6 weeks) and then subsequently at 3, 6, 9, 12 and 18Mattos et al. concluded that the majority of stenoses
months (Fig. 1).detected in their patients remained patent whether
they were revised or not.15
There have been two small published randomised
Randomisationcontrolled trials comparing duplex to clinical assess-
ment in lower limb bypasses. Lundell et al. studied
Patients who may be eligible for entry into the trialboth vein (n=106) and synthetic grafts (n=50) ran-
are informed of the study with the aid of a patientdomised to either an ‘intensive’ surveillance of clin-
information leaflet. If they agree to participate, byical examination, ankle–brachial pressure index
providing written consent, and satisfy all the inclusion(ABPI) and duplex scans or ‘routine’ surveillance of
criteria, they are entered into the trial at their firstclinical examination and ABPI only.16 Their results
follow-up appointment, approximately 6 weeks aftershowed that at three years post-operation there was
their operation. The patient’s general practitioner isan advantage to duplex scanning the vein bypasses notified of the patient’s inclusion in the trial and is
when comparing patency rates, but not amputation provided with a summary of the trial protocol.
rates. More recently, Ihlberg et al. could not dem- The allocation of a patient’s group is performed by
onstrate any difference in limb salvage between du- a computer randomisation service provided by the
plex surveillance and clinical assessment in their University of York, via a free-phone number. The
randomised controlled trial of 185 consecutive vein operator checks the patient’s details against the eli-
grafts.17 However, they had difficulty in obtaining gibility criteria given above, issues the patient’s follow-
complete data on patients and had a small cohort of up group (clinical or duplex) and a unique study
patients per group. These papers suggest the need number. The randomisation is stratified by centre and
for a large randomised controlled trial. presenting symptoms (claudication or critical isch-
In response to this need we have set up a clinical aemia).
trial, the Vein Graft Surveillance Trial, to assess
amputation rates, graft patency, quality of life and 1. Clinical outcomes.
health care costs in 1200 patients from 50 centres in Baseline data are obtained from the patient’s hospital
the U.K. and Europe. The main question to be tested notes, collected at the time of the first follow-up ap-
in this trial is whether there is a difference between pointment. This includes details of the operation per-
formed, the patient’s smoking history, any anti-plateletduplex surveillance and clinical assessment fol-
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Fig. 1. Randomisation and follow-up procedure in the Vein Graft Surveillance Trial.
or lipid-lowering medications at the time of operation, trial, the patient’s ABPI is measured, any presenting
symptoms noted and any surgical or radiological inter-their diabetic status and pre-operative ABPI.
At each follow-up appointment, in both arms of the vention performed recorded. In addition, whether the
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patient is smoking at that time and taking any anti- 1000 patients will allow detection of a 7-point dif-
ference in 7 of 8 SF-36 scales and a 3.5 difference in 4platelet or lipid-lowering medications is reported. The
duplex group are scanned according to usual local of the domains.19 However, it is envisaged that 5% of
patients will be lost to follow-up and a mortality ratepractice and these results are recorded; in particular
whether the peak systolic flow velocity along the entire of approximately 5% will occur. The aim is therefore
to recruit 1200 patients in total.graft is less than 45 cm/sec18 and, if a stenosis is
detected, the V2/V1 ratio.7 Any other irregularities,
such as inflow/outflow problems, graft dilatation or
arterio-venous fistula, are also noted. At 18 months Results: data management and statistical
the clinical group also have a duplex scan, so that the analysis
incidence of vein graft stenosis at this time can be
evaluated. Follow-up data are collected during routine out-
patient visits, completed by the consultant, research
2. Costs. nurse or vascular technologist at each centre. All data
Hospital resource use of all the patients in the study are recorded in duplicate; the top copy is sent to the
will be compared. The number of duplex scans, an- co-ordinating centre for entry into a central database,
giograms and angioplasties, thrombolysis and surgical whilst the duplicate copy remains in the patient’s file
interventions performed are recorded. The prices of at the centre of origin. Validation of the data recorded
the different resources used will be estimated from a will be performed on a randomly selected proportion
number of different hospital financial records to allow of the patients across all centres.
for regional variations. A small executive committee are responsible for the
progress of the trial. The recruitment rates in each
3. Quality of life. centre are monitored using a hospital log form of all
These data are collected at 6 and 18 months using the femorodistal operations performed and whether or
SF-36 and EuroQol questionnaires.19–21 The Medical not they are entered into the trial. This is essential,
Outcomes Study 36-item short form health survey (SF- not only to encourage recruitment, but also to ensure
36) is a generic measure that produces an eight-di- that the patient population entered into the study are
mensional profile as well as two summary measures of representative of the true population of infrainguinal
health status (physical and mental component scores). vein bypasses and have not been pre-selected for entry.
The EuroQol provides two single-index measures of No interim analyses for possible early termination
health status. Both questionnaires have been previously of the trial will be used, and the trial’s results will not
used to analyse the impact of lower limb ischaemia on be made known to the participating centres until the
quality of life.22,23 The SF-36 and EuroQol questionnaires end of the trial. The principal statistical analyses are on
areself-administered,completedbythepatientsprior to an intention-to-treat basis. Comparison of amputation
any consultation with either the vascular technologist/ rates will be made at 18 months, using life-table
radiologist or consultant to ensure a consistent measure methods which include deaths due to vascular causes
of the patient’s feelings. as an adverse outcome. The proportions of patients
with primary, primary assisted and secondary graft
patency at 18 months will be compared between the
randomised groups. As subgroup analyses, assessedSample size
by tests of interaction, the results for patients with
claudication will be compared with those for patientsUsing the review of Golledge et al., around 10% of
with critical ischaemia.patients had amputations within the follow-up period
of the studies.5 The main result of the current trial will
be expressed as the difference in the proportions of
patients who have an amputation, within 18 months Health economics and quality of life
of the original vein graft operation, between the duplex
and clinical groups. A trial of 1000 patients (500 in In the event that the study demonstrates health gain
with extra costs, the cost and quality-of-life data willeach group) estimates such a difference with a standard
error (s.e.) of 1.9%. Such a trial has a power of 90% to be combined in the form of a cost utility analysis. On
the other hand, if there are cost-savings for either armdetect, as statistically significant at the 5% level, a
difference in amputation rates between 10% and 5%. and no loss in quality of life, any saving will be
quantified.With respect to qualify-of-life data, the recruitment of
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Using costs and quality-of-life data collected as part St Hellier Hospital, London
St Thomas’ Hospital, Londonof the study it will be possible to ascertain whether
the study has excluded a quality-of-life gain achievable Southmead Hospital, Bristol
Stafford District General Hospitalat reasonable cost due to duplex surveillance. If the
study’s results exclude a clinically important difference Stobhill Hospital, Glasgow
Victoria Hospital, Blackpooldue to the use of duplex surveillance, the number of
duplex scans and their cost, which may be avoided if Walsgrave Hospital, Coventry
surveillance were abandoned, will be estimated. This
result, when disseminated, would make managers and
clinicians be more selective in the purchase and use E.U. Trial Centres (to 1.12.98)
of duplex facilities. However, if the findings indicate
that duplex surveillance leads to an improvement in Bassini Teaching Hospital, Italy
health status, this will be set against any extra costs General Hospital of Harburg, Germany
to facilitate resource prioritisation. Helsinki Uni. Central Hospital, Finland
Instituto Vascular de Lisboa, Portugal
Istanbul Med. Faculty, Turkey
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